The normal skin and other tissues of adult genetically mast cell-deficient WBB6Fl-W/W' or WCB6F,-SI/Sld mice contain less than 1 .O% the number of mast cells present in the corresponding tissues of the congenic normal ( + / + 1 mice.
respectively; the corresponding values for vehicle-treated skin were 1.5 5 1 .0/mm2 and 145 * 8/mm2, respectively.
DOUBLE DOSE O F mutant genes at the Wor SI locus
A of the mouse can produce a constellation of phenotypic abnormalities that includes a macrocytic anemia, a lack of hair pigmentation, sterility, and a profound mast cell deficiency.'.' However, the mechanisms responsible for these Recently, certain W locus mutations have been shown to be closely linked to4 or actually involve5 the gene for the putative tyrosine kinase receptor c-kit. Because c-kit exhibits significant homology to the receptors for colony-stimulating factor-1 (CSF-1) and platelet-derived growth factor (PDGF), the stem cell defect in W / W mice probably reflects the expression by the affected lineages of quantitative and/or qualitative abnormalities of the c-kit p r o d~c t .~.~ By contrast, the defect responsible for the mast cell deficiency of S I mutants, such as the WCB6F,-S1/Sld (Sl/Sld) mouse, lies in a microenvironmental factor(s) required for the maturation/ differentiation of this lineage. Thus, even though SI/Sld mice are themselves anemic and profoundly mast cell-deficient, SI/Sld bone marrow cells can cure the anemia and mast cell deficiency of WBB6FI-W/W m i~e .~.~ Furthermore, while transplantation of congenic normal (+ / +) bone marrow cells into SI/Sld mice has no effect on the mutants' anemia or mast cell defi~iency,~.~ introduction of 3T3 fibroblasts of WCB6FI-+ / + origin into WCB6F,-SI/Sld mice results in the local development of mast cells in association with the adoptively transferred fibroblast^.'.^
We have been searching for additional insights into the expression of genetically determined mast cell deficiencies by identifying and analyzing settings in which this abnormality can be reversed in vivo. We showed previously that the cutaneous mast cell deficiency of W / W mice underwent repair at sites of chronic idiopathic dermatitis.' The mast
The PMA-induced dermal mast cells in W/W' mice appeared mature by morphology, stained with the heparinbinding fluorescent dye, berberine sulfate, and were competent to express IgE-dependent passive cutaneous anaphylaxis responses. The development of mast cells was a local, not systemic, effect of PMA treatment. PMA treatment also induced dermatitis in both WCB6Fl-S//Sld and + / + mice, but was associated with increased numbers of dermal mast cells only in the WCB6Fl-+ / + mice.
PMA treatment had no detectable effect on the ability of bone marrow-derived cultured mast cells to survive in the skin of Sl/Sld mice. These findings establish a convenient model system for analyzing factors associated with the development of endogenous populations of mast cells in genetically mast cell-deficient W/W' mice. 0 1990 by The American Society of Hematology.
cells that developed a t sites of dermatitis were indistinguishable from those in the skin of the +/+ mice by light or transmission electron microscopy, or by staining with the heparin-binding fluorescent dye, berberine sulfate.' Thus, they resembled normal mature dermal mast cells.','0 SI/Sld mice also developed a chronic idiopathic dermatitis'; however, in this mutant, dermatitis was not associated with the development of recognizable mast cell populations. ' Chronic idiopathic dermatitis theoretically provides an opportunity to search for factors that locally overcome the stem cell abnormality responsible for the mast cell deficiency of W / W mice, eg, changes in the expression of c-kit by cells in the mast cell lineage, alterations in local levels of the as yet unidentified c-kit ligand, or the local production of other factors that influence mast cell proliferation or development. However, the etiology of chronic idiopathic dermatitis is unknown, the condition affects only a minority of susceptible animals, and mice generally do not exhibit dermatitis before the age of 8
We therefore decided to search for a chemically defined agent capable of predictably inducing mast cell development in the skin of W / W mice.
We decided to begin our investigation with the phorbol ester, phorbol 1Zmyristate 13-acetate (PMA) for three reasons. In normal mice, the repeated epicutaneous applica-
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tion of PMA (or PMA-containing preparations such as croton oil) induces a chronic dermatitis associated with epidermal hyperplasia and dermal thickening,I3-l5 features also observed in chronic idiopathic dermatitis.8*".'2 Repeated applications of croton oil or PMA also can cause hyperplasia of dermal mast
In addition, the interaction of PMA with protein kinase C directly activates many cell types that can also respond to signals mediated through cell-surface receptors for specific ligand^.'^." We found that the repeated application of PMA induced a striking and dose-dependent increase in the number of dermal mast cells in W / W mice. Sl/Sld mice treated with PMA developed a dermatitis similar to that of PMA-treated W/W" mice, but demonstrated no change in their dermal mast cell deficiency. Some of our results have been reported in abstract form.18 PMA (Sigma Chemical Co, St Louis, MO) was dissolved in acetone (HPLC grade; Fisher Scientific Co, Fair Lawn, NJ) at appropriate concentrations and stored at -7OOC. Three times per week, each mouse was lightly anesthetized with ether, and 5 pL of phorbol ester solution was applied evenly by micropipet over the entire dorsal surface of the animal's left ear, while 5 pL of acetone alone was applied similarly to the right ear. In some experiments, the animals were treated on the left ear with PMA but received no acetone treatment on the right ear.
MATERIALS AND METHODS

Animals
At various intervals during the course of the experiments, the thickness of PMAtreated or acetone-treated (control) ears was measured with a micrometer as previously described, and the results were expressed in inches x 10-4.20 At various intervals after initiating treatment, the mice were killed with ether, and their ears were amputated; a central strip of each ear was then fixed and processed for 1 pm Eponembedded sections that were stained with Giemsa solution.21.22 Representative similar tissues were also processed for subsequent staining with berberine sulfate as previously described." Berberine sulfate is a fluorescent cationic dye that binds to heparin in the cytoplasmic granules of mature "connective tissue-type'' mast cells, such as those normally present in the skin of mice.',"'
In some experiments, we examined the anatomical distribution of mast cells in animals treated on one ear with PMA. Various grossly normal tissues other than skin, including the tongue, forestomach, glandular stomach, duodenum, cecum, lung, and spleen, were processed for 1 ym sections. We also examined the animals' resident peritoneal cells, obtained by peritoneal lavage with 10 mL of Hanks' balanced salt solution (HBSS; GIBCO Ltd, Grand Island, NY) containing 1% bovine serum albumin (Pentex, fraction V; Miles Diagnostics, Kankakee, IL). Cytocentrifuge preparations of the peritoneal cells and the 1 pm tissue sections were stained with
Treatment of animals.
Assessment of the effects of PMA treatment.
Giemsa solution, and the numbers of mast cells were determined by microscopic examination of the slides.
Quantitation of tissue mast cells. The quantitation of mast cells in the tissues was performed as previously described.s.23 Briefly, the Giemsa-stained 1 pm sections were examined by light microscopy at 400x, and the numbers of mast cells present were recorded. The same tissue section was then projected onto a piece of paper with a Leitz Type XI C Xenon slide projector (Leitz, Rockleigh, NJ), and the outlines of the epidermis, dermis, and cartilage were traced. The area of the dermis was determined by analyzing the projected images using a MOP-3 digitizer (Zeiss, New York, NY) interfaced to an HP-86 computer (Hewlett-Packard Co, Palo Alto, CA). The area of the dermis was taken as the total area, on the dorsal aspect, between the dermal-epidermal junction and the superficial surface of the cartilage. The numbers of mast cells are expressed as the number of cells per mm2 of dermis t SEM. The statistical significance of differences in the mean values for groups was calculated using Student's t tests (two-tailed; paired test for left ear versus right ear comparison, unpaired for comparisons between groups).
Assessment of the functional maturity of the PMA-induced cutaneous mast cells. In order to demonstrate that the PMAinduced mast cells present in the ear skin of the treated mice were functionally active, we tested their ability to mediate IgE-dependent passive cutaneous anaphylaxis, a classic type I hypersensitivity response.24 We injected, into both ears of W/W" or + / + mice that had been treated on only one ear with 5 pg of PMA for 6 weeks, either 20 pL of phosphate-buffered saline (PBS) or -50 ng of monoclonal IgE anti-DNP antibody (as ascites containing the monoclonal antibody H 1 DNP-(-2625) in 20 pL of PBS. After 24 hours, the mice were challenged intravenously with 100 pg of DNP,,,, human serum albumin (HSA) in 200 pL of a PBS solution containing 1 .O% Evans Blue dye (Sigma). The ear swelling responses of the mice (A = experimental value -baseline measurement taken before antigen challenge) were measured at 10.20, and 30 minutes, and at 1,2, and 4 hours after antigen challenge and expressed as A x inch, as previously described.20.24 At 4 hours, the mice were killed and specimens of the ears were processed for 1 pm Eponembedded, Giemsa-stained sections as above.
Donor WCB6F1-+/+ mice were sacrificed with ether, and their tibiae and femora were removed. The marrow was excised from the bones, and the cells were maintained in long-term culture in the presence of conditioned medium containing IL-3 (supernatants of concanavalin A-stimulated spleen cells), as previously described.w6 After 5 weeks, at least 97.0% t 3.0% of cells that remained in the cultures (99% viability by Trypan blue exclusion) were identifiable as mast cells, as determined by counting with neutral red.7 Bone marrow-derived, cultured mast cells (BMCMC) such as these are best regarded as immature mast cells that express certain similarities to "mucosal" type mast cells (reviewed in references 26 through 28). BMCMC, however, can acquire multiple phenotypic features of mature "connective tissuetype" mast cells (CTMC) upon transfer into anatomical sites in WBB6FI-W/W' mice, such as the skin or peritoneal cavity, where CTMC occur in normal mice.i0,27,2s For intradermal injection (20 pL per site), BMCMC were resuspended in HBSS to provide 5 x lo5 mast cells per 20 pL volumes. Effecr of PMA treatment on the survival of transplanted BMCMC in WCB6F,-SI/Sld mice. The left ears of WCB6F,-Sl/ SI', WCB6F,-+/+, and WBB6FI-W/W' mice were treated with 5 pg of PMA 3 times weekly for 2 weeks. After 2 weeks, 5 x los BMCMC were injected into the dermis of the left and right ears of the WCB6F,-SI/Sld mice, and into the right ears only of the WBB6F,-W/W" animals. The PMA treatments were continued, as above, for an additional 6 weeks (ie, for 8 weeks in total), and then the animals were killed and their ears processed for histology.
Culture of bone marrow-derived mast cells.
For personal use only. of PMA were applied, three times weekly, to the left ears of W / V and +/+ mice, and acetone alone was applied similarly to the right ears. After 6 weeks, the ears were processed for histology and analyzed to determine the effect of the treatment. As previously reported for normal mice,13 histologic examination showed that repeated epicutaneous application of PMA induced epidermal hyperplasia and a substantial thickening of the dermis with an associated dermal infiltrate of inflammatory cells, consisting predominantly of neutrophils. The extent of the chronic dermatitis induced by the PMA treatment, as reflected both in total ear thickness (Fig 1) and the histologic findings, was dependent on the dose applied. PMA (10 pg) did not induce significantly greater reactions than did the application of 5 pg of PMA (Fig 1) . Treatment with acetone alone had no detectable effect on ear thickness (Fig 1) . At each dose of PMA tested, the effects on ear thickness observed in W/W ( Fig   1A) or congenic + / + (Fig 1B) mice were statistically indistinguishable (P > .05 for all comparisons).
We also applied 5 pg of PMA or 5 pL of acetone to the ears of another group of mice, as above, but for either 3 or 6 weeks. Again, acetone had no effect on ear thickness, whereas PMA treatment resulted in significant thickening. There were no significant differences in the effect on ear thickness of PMA given for 3 or 6 weeks, in either WBB6F,-W/W'or -+/+ mice (data not shown). By contrast, treatment with repeated applications of PMA was associated with dose-dependent increases in the numbers of dermal mast cells in both the genetically mast celldeficient W/W' (Fig 2A) and the congenic normal (+/+) animals (Fig 2B) . Thus, no significant increases in dermal mast cell numbers were observed in the ears of mice that had been treated with only 5 ng of PMA for 6 weeks, but significantly increased numbers of mast cells were observed at all higher doses of PMA tested. The coefficients of correlation for the doses of PMA applied to the ears and the numbers of dermal mast cells per square millimeter of dermis after 6 weeks of treatment were highly significant (for W/W mice, r = .946, P < .01; for +/+ mice, r = 328, P < .05).
Repeated epicutaneous application
Although the extent of ear thickening reached its plateau 3 weeks after initiation of PMA treatments, the numbers of identifiable mast cells only began to increase at 3 weeks, and ... However, when the PMA-induced dermal thickening was taken into account and the data were expressed as the number of mast cells/mm2 of dermis (Fig 3) , there were no significant differences at this time in the values for the ears of the PMA-and acetone-treated animals. At 6 weeks after the initiation of treatment, the numbers of mast cells per square millimeter of dermis were markedly elevated in both the W / W (Fig 3A) and congenic + / + (Fig 3B) The mast cells present in the PMA-treated ears of both W/W' and congenic + / + mice were especially frequent in the more superficial aspects of the dermis (Fig 4) . In the W/W animals. we often observed loose clusters of 2 to 4 mast cells (Fig 4B. insert) and rarely found mast cells undergoing mitosis (Fig 4C through F) The induction of mast cell development is a local. not a systemic. consequence of PMA treatment. In five WBB6F,-W/W' mice that had developed dermal mast cells in ears treated for 6 weeks with PMA. we also examined biopsies of the tongue. forestomach. glandular stomach, duodenum, cecum. lungs and spleen. and examined the resident peritoneal cells in cytocentrifuge preparations. We found no mast cells whatsoever in any of these anatomical sites.
Repeated epicutaneous application of PMA induces dermatitis in WCB6F,SI/SId mice. hut is not associated with the development of dermal mast cells. Three or six weeks of treatment with PMA (5 pg per application, three times per week) induced thickening of the ears of WCB6F,-SI/SId or -+ / + mice (Fig 6A) that was very similar to the responses observed in PMA-treated WBB6FI-W/W'or -+/+ animals.
The dermatitis induced by PMA in WCB6F, mice was also similar to that induced by PMA in WBB6F, mice by histology. However. PMA treatment was not associated with the development of mast cells in the WCB6F,-SI/Sld mice (Fig 6B) . After 3 or 6 weeks of treatment with 5 pg PMA. there was still less than 1 mast cell/mm* of dermis in the SI/SId mice; even 12 weeks of high-dose PMA treatment (IO pg PMA, three times weekly) did not induce mast cell development in the treated ears of SI/SId mice (less than I mast cell/mm* of dermis). In contrast. PMA did induce increased levels of mast cells in the WCB6F,-+/ + mice ( Fig   6B) .
PMA treatment of WCB4F,Sl/Sld mice does not render the dermal microenvironment of these mice hospitable for mast cell growth/maturation. IL-34ependent BMCMC By contrast, transplantation of congenic + / + bone marrow cells into WCB6F,-SI/Sld mice has no effect on the mast cell deficiency of this The preceding series of experiments showed that PMA treatment induced dermatitis in SI/Sld mice, but not the development of dermal mast cells from mast cell precursors of SI/Sld origin. However, we also investigated whether PMA-induced dermatitis rendered the SI/Sld dermal microenvironmental tolerant of the survival and/or maturation of BMCMC, which are more mature than the circulating mast cell precursor. We treated the left ears of WCB6Fi-SI/ SId mice with PMA for 2 weeks to induce an inflammatory response, then injected 5 x lo5 BMCMC of WCB6Fl-+ / + origin into the dermis of both ears of these animals. The left ears were then treated with PMA for an additional 6 weeks in order to maintain the inflammatory response. The mice were then killed, and their ears were processed for histology. To provide a positive control group of mice whose dermal microenvironment was competent for mast cell development, we injected aliquots of the same WCB6FI-+/+ BMCMC into the untreated ears of WBB6Fl-W/W" mice, then processed the transplanted ears for histology 6 weeks later.
As shown in Table 1 There are several possible mechanisms by which PMA treatment might reverse the dermal mast cell deficiency of the W/W" mouse. Sonoda et all' showed that the expanded population of dermal mast cells in the PMA-treated back skin of C57BL/6-bgJ/bgJ -C57BL/6-+ / + chimeric mice was derived from both C57BL/6-+/+ mast cells or their precursors already present in the skin, as well as from C57BL/6-bgJ/bgJ mast cell precursors recently derived from the bone marrow. In our experiments, PMA might have directly influenced the recruitment and development of circulating W / W mast cell precursors at the treated site and/or affected the small number of mast cells or their precursors normally present in the skin of the mutants. If The development of increased numbers of morphologically recognizable mast cells a t sites of PMA application in W / W mice required prolonged periods of treatment. Taguchi et a1 reported that a single application of PMA transiently augmented the histamine content and histidine decarboxylase activity of W/W skin.32 Because this effect was not associated with the development of recognizable mast cells a t the treated sites and was greatly attenuated in irradiated mice, the finding was thought to reflect the infiltration into PMAtreated sites of leukocytes with histamine synthetic ability.'* When we examined the ear skin of W / W mice up to 36 hours after a single epicutaneous application of 10 pg of PMA, no change in the animals' dermal mast cell deficiency was detectable." In the present study, increased numbers of mast cells were only marginally detectable after 3 weeks of treatment with PMA a t 5 pg per application. However, by 6 weeks after the beginning of PMA treatment at 5 pg per application, numbers of mast cells per square millimeter dermis in the skin of W / W mice exceeded those in contralateral control (acetone-treated) ears by greater than %fold.
For personal use only. on November 15, 2017. by guest www.bloodjournal.org From PMA-induced mast cell hyperplasia also occurs in normal mice.l3'I5 In our experiments, both WBB6F,-+ / + and WCB6Fl-+ / + mice developed significantly increased numbers of dermal mast cells at sites treated repeatedly with PMA. By contrast, genetically mast cell-deficient WCB6F,-S1/Sld mice did not develop mast cells at sites of PMAinduced dermatitis, even when treatment with high doses of the agent (10 pg per application) were continued for 12 weeks. These findings and those of our previous study* indicate that a microenvironmental factor defective in the SI/Sld mouse, presumably the product of the SI locus, must be adequately expressed to permit detection of the effects of either chronic idiopathic dermatitis or chronic PMA treatment on mouse mast cell populations in vivo. 
